-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] The industry believes that volume procurement has a positive impact on large companies and cost-effective products
.
Pharmaceutical stocks are now in a state of correction
.
It is reported that as soon as the market opened on December 8, the pharmaceutical stocks of Hong Kong stocks ushered in a general rise
.
For example, as of the close in the afternoon, Zai Lab rose by more than 10%, GenScript, Via Bio, and Clover Bio rose by more than 6%, WuXi Biologics rose 4.
95%, and Kangfang Biotech rose 3.
65%
.
A number of brokerage research reports said that the current valuation of the pharmaceutical sector is relatively in the bottom area
.
In the long run, the investment in the pharmaceutical sector is cost-effective and has outstanding growth potential.
Investors can choose an opportunity to intervene in bargaining
.
On the news of Zai Lab, Zai Lab recently announced that Zele (Niraparib) has been included in the National Medical Insurance Drug Catalogue newly released by the National Medical Insurance Administration of China (National Medical Insurance Administration) for the treatment of advanced epithelial ovarian cancer, First-line maintenance therapy after a response to platinum-containing chemotherapy in adult patients with fallopian tube or primary peritoneal cancer (collectively referred to as ovarian cancer), regardless of biomarker status
.
On the news from GenScript, GenScript Biotechnology recently issued an announcement.
Legend Bio, a non-wholly-owned subsidiary of the company, announced that its partner Janssen Pharmaceutical Co.
, Ltd.
(Janssen) submitted a submission to the Ministry of Health, Labour and Welfare (MHLW) of Shida Keoran New Drug Application (NDA) for cilta-cel
.
It is reported that cilta-cel is a chimeric antigen receptor T-cell (CAR-T) therapy, previously known as JNJ4528 in the United States and Europe, and known as LCAR-B38M in China cell therapy
.
cilta-cel is currently conducting multiple clinical studies for the treatment of patients with relapsed or refractory multiple myeloma and more front-line therapy.
It is a CAR with a differentiated structure composed of two single-domain antibodies targeting BCMA.
-T
.
On the news of Via Bio, recently, Bichen Pharmaceuticals, an investment company of Via Bio, announced that its self-developed BRAF inhibitor ABM-1310 clinical trial application has been approved by the NMPA, allowing the company to carry out I Phase clinical trials
.
Currently, the Phase 1 clinical trial of ABM-1310 is well underway in the United States, and the initial data have shown good safety and positive information
.
It is reported that Bichen Pharmaceuticals is one of the innovative pharmaceutical companies that Via Bio has participated in the investment and incubation, which is also a specific case of Via Bio’s service-for-stock (EFS) business
.
According to the interim report, in the first half of this year, the company's revenue from EFS was 72 million yuan, accounting for about 6.
98% of its revenue
.
On the news of Clover Bio, Clover Bio recently issued an announcement that on December 7, 2021, the company's wholly-owned subsidiary, Clover Biopharmaceuticals (Hong Kong) Co.
, Limited (Clover Hong Kong), entered into an agreement with United Nations Children's Fund (UNICEF).
Long Term Agreement (Vaccine Supply Agreement)
.
WuXi Biologics WuXi Biologics can provide end-to-end services to meet the needs of customers at all stages.
At the same time, it also has the R&D and production capabilities of various mainstream biological products, and can provide CRO/CMO services for more types of customers.
It has a wide range of target customer group
.
With the advantages of strong biological drug development capabilities, efficient cell expression and production platforms, and the speed of industry project delivery, WuXi Biologics has strong customer acquisition capabilities for early-stage R&D projects
.
The company also closely follows the development trend of the industry to carry out forward-looking layout, continue to develop new technology platforms and expand business areas, which will further broaden the company's customer base and enhance the company's ability to acquire customers
.
In addition, WuXi Biologics has been deeply engaged in the field of biopharmaceutical CMO/CDMO for many years, with high production efficiency and good stability
.
On the whole, the key elements of WuXi Biologics' success have not changed, and the advantages will continue, which is expected to drive the company's long-term rapid growth
.
On the news of Kangfang Bio, Kangfang Bio announced that it will support an investigator-initiated clinical study to evaluate the company's novel caldoniri (PD-1 / CTLA-4 bispecific antibody, R&D code: AK104) in the United States ) for the treatment of neuroendocrine cervical cancer efficacy and safety
.
It is reported that Cardonil is a novel and potential next-generation PD-1/CTLA-4 bispecific tumor immunotherapy backbone drug independently developed by the company.
The main indications include liver cancer, cervical cancer, lung cancer, gastric cancer, esophageal squamous cell carcinoma and Nasopharyngeal cancer,
etc.
.
Pharmaceutical stocks are now in a state of correction
.
It is reported that as soon as the market opened on December 8, the pharmaceutical stocks of Hong Kong stocks ushered in a general rise
.
For example, as of the close in the afternoon, Zai Lab rose by more than 10%, GenScript, Via Bio, and Clover Bio rose by more than 6%, WuXi Biologics rose 4.
95%, and Kangfang Biotech rose 3.
65%
.
A number of brokerage research reports said that the current valuation of the pharmaceutical sector is relatively in the bottom area
.
In the long run, the investment in the pharmaceutical sector is cost-effective and has outstanding growth potential.
Investors can choose an opportunity to intervene in bargaining
.
On the news of Zai Lab, Zai Lab recently announced that Zele (Niraparib) has been included in the National Medical Insurance Drug Catalogue newly released by the National Medical Insurance Administration of China (National Medical Insurance Administration) for the treatment of advanced epithelial ovarian cancer, First-line maintenance therapy after a response to platinum-containing chemotherapy in adult patients with fallopian tube or primary peritoneal cancer (collectively referred to as ovarian cancer), regardless of biomarker status
.
On the news from GenScript, GenScript Biotechnology recently issued an announcement.
Legend Bio, a non-wholly-owned subsidiary of the company, announced that its partner Janssen Pharmaceutical Co.
, Ltd.
(Janssen) submitted a submission to the Ministry of Health, Labour and Welfare (MHLW) of Shida Keoran New Drug Application (NDA) for cilta-cel
.
It is reported that cilta-cel is a chimeric antigen receptor T-cell (CAR-T) therapy, previously known as JNJ4528 in the United States and Europe, and known as LCAR-B38M in China cell therapy
.
cilta-cel is currently conducting multiple clinical studies for the treatment of patients with relapsed or refractory multiple myeloma and more front-line therapy.
It is a CAR with a differentiated structure composed of two single-domain antibodies targeting BCMA.
-T
.
On the news of Via Bio, recently, Bichen Pharmaceuticals, an investment company of Via Bio, announced that its self-developed BRAF inhibitor ABM-1310 clinical trial application has been approved by the NMPA, allowing the company to carry out I Phase clinical trials
.
Currently, the Phase 1 clinical trial of ABM-1310 is well underway in the United States, and the initial data have shown good safety and positive information
.
It is reported that Bichen Pharmaceuticals is one of the innovative pharmaceutical companies that Via Bio has participated in the investment and incubation, which is also a specific case of Via Bio’s service-for-stock (EFS) business
.
According to the interim report, in the first half of this year, the company's revenue from EFS was 72 million yuan, accounting for about 6.
98% of its revenue
.
On the news of Clover Bio, Clover Bio recently issued an announcement that on December 7, 2021, the company's wholly-owned subsidiary, Clover Biopharmaceuticals (Hong Kong) Co.
, Limited (Clover Hong Kong), entered into an agreement with United Nations Children's Fund (UNICEF).
Long Term Agreement (Vaccine Supply Agreement)
.
WuXi Biologics WuXi Biologics can provide end-to-end services to meet the needs of customers at all stages.
At the same time, it also has the R&D and production capabilities of various mainstream biological products, and can provide CRO/CMO services for more types of customers.
It has a wide range of target customer group
.
With the advantages of strong biological drug development capabilities, efficient cell expression and production platforms, and the speed of industry project delivery, WuXi Biologics has strong customer acquisition capabilities for early-stage R&D projects
.
The company also closely follows the development trend of the industry to carry out forward-looking layout, continue to develop new technology platforms and expand business areas, which will further broaden the company's customer base and enhance the company's ability to acquire customers
.
In addition, WuXi Biologics has been deeply engaged in the field of biopharmaceutical CMO/CDMO for many years, with high production efficiency and good stability
.
On the whole, the key elements of WuXi Biologics' success have not changed, and the advantages will continue, which is expected to drive the company's long-term rapid growth
.
On the news of Kangfang Bio, Kangfang Bio announced that it will support an investigator-initiated clinical study to evaluate the company's novel caldoniri (PD-1 / CTLA-4 bispecific antibody, R&D code: AK104) in the United States ) for the treatment of neuroendocrine cervical cancer efficacy and safety
.
It is reported that Cardonil is a novel and potential next-generation PD-1/CTLA-4 bispecific tumor immunotherapy backbone drug independently developed by the company.
The main indications include liver cancer, cervical cancer, lung cancer, gastric cancer, esophageal squamous cell carcinoma and Nasopharyngeal cancer,
etc.
